The precursor of EGCG, pro-epigallocatechin gallate (pro-EGCG), reduces the formation of new blood vessels in endometrial cancer by down-regulating vascular endothelial growth factor A (VEGFA), HIF-1α and C-X-C motif chemokine ligand 12 (CXCL12), which is achieved by inhibiting the PI3K/Akt/mTOR/HIF-1α pathway (52). This evidence concerns the gene CXCL12 and endometrial cancer.